Israel's med tech brand Inspira plans entry into Southeast Asia and South American markets

Inspira Technologies, a breakthrough medical technology company based in Israel, has announced the AMAR submission for approval of the INSPIRA ART100, marking a significant milestone in Inspira's venture into new markets.

The company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. 

AMAR - the Israeli Ministry of Health's medical device regulation unit, is the authority responsible for controlling medical device licenses and approvals including the issuance of certificates of free sale which are necessary for marketing regulatory approvals in the Southeast Asia and South American markets, potentially propelling the company towards targeting exceptional growth opportunities.

The INSPIRA ART (Gen 2) utilises adaptive blood oxygenation technology to continuously measure the patient's blood parameters in real-time to deliver needed oxygen volume straight into the blood. The unique technology is designed to allow for the targeted control of oxygenation levels, thereby adapting to the individual needs of each patient. This method is expected to significantly reduce complications associated with traditional ventilation methods, shorten hospital stays and potentially save lives.